Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Phase 2 Active not recruiting 408 enrolled Alumis Inc

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.

Timeline

Start: 2023-06-26
Primary completion: 2026-07-01
Completion: 2027-09-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ENVUCITINIB	Small molecule	—	Oral

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Summary

Timeline

Drugs

Indications